Skip to main content
Equibles
TSHA logo

TSHA · Taysha Gene Therapies, Inc.

Track TSHA — free

Use TSHA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about TSHA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$5.95 -0.04 (-0.67%) At close · Aug 14
Market Cap
$2.09B
Shares
325.83M

Taysha Gene Therapies, Inc. Earnings Call Transcripts

Every quarterly earnings call for Taysha Gene Therapies, Inc. (TSHA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $4.71M −$17.62M '23 Q1 23-05-15 · $2.40M −$24.60M '23 Q2 23-08-14 · $4.75M −$117.09M '23 Q3 23-11-14 · $3.60M $47.74M '23 Q4 24-03-19 ▼27.5% $3.41M −$24.06M '24 Q1 24-06-26 ▼53.6% $1.11M −$20.93M '24 Q2 24-08-12 ▼62.3% $1.79M −$25.52M '24 Q3 24-11-13 ▼43.9% $2.02M −$18.79M '24 Q4 25-02-26 ▼32.5% $2.30M −$21.53M '25 Q1 25-05-15 ▲78.6% $1.99M −$26.88M '25 Q2 25-08-12 ▼100% $ −$32.73M '25 Q3 25-11-04 ▲171.3% $5.49M −$27.85M '25 Q4 26-03-19 ▼100% $ −$42.41M '26 Q1 26-05-06 LATEST ▼100% $ −$46.64M '26 Q2 26-08-11
Earnings call
FY26 · Q2
2026-08-11
Taysha Gene Therapies Second Quarter 2026 Financial Results Conference Call
Confident tone TASHA-102 clinical development Regulatory pathway and FDA engagement Rett Syndrome Scientific Meeting (IRSF) data
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-22
TSHA-102 Rett Syndrome Program Update Conference Call
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Taysha Gene Therapies, Inc. Q1 FY2026 Earnings Call
Confident tone Rett syndrome patient population and unmet need TASHA-102 (Tayshia 102) profile and efficacy Competitive positioning vs. ICV administration
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Taysha Gene Therapies, Inc. Q4 FY2025 Earnings Call
Confident tone Regulatory Progress with FDA Rett Syndrome Market Opportunity TASHA-102 Clinical Development
Revenue
$5.49M*
▲ 171.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Taysha Gene Therapies, Inc. Q3 FY2025 Earnings Call
Confident tone TASHA-102 REVEAL clinical data in Rett Syndrome Pivotal trial initiation and enrollment Commercial and launch team building
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Taysha Gene Therapies, Inc. Q2 FY2025 Earnings Call
Confident tone FDA and Regulatory Alignment TASHA-102 / REVEAL Pivotal Trial Natural History Data Set
Revenue
$1.99M
▲ 78.6% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Taysha Gene Therapies, Inc. Q1 FY2025 Earnings Call
Confident tone FDA regulatory alignment Rett syndrome disease and natural history data TSHA-102 clinical safety and efficacy
Revenue
$2.30M
▼ 32.5% YoY
Diluted EPS
$-0.08
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Taysha Gene Therapies, Inc. Q4 FY2024 Earnings Call
Confident tone Regulatory Pathway and FDA Alignment TSHA-102 Clinical Safety Profile Dose Escalation Completion and Dataset
Revenue
$2.02M*
▼ 43.9% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Taysha Gene Therapies, Inc. Q3 FY2024 Earnings Call
Confident tone TSHA-102 lead program for Rett Syndrome Clinical efficacy observations Clinical safety and dosing
Revenue
$1.79M
▼ 62.3% YoY
Diluted EPS
$-0.10
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Taysha Gene Therapies, Inc. Q2 FY2024 Earnings Call
Confident tone TSHA-102 clinical progress and dosing Rett Syndrome disease profile and unmet need Regulatory strategy and FDA interaction
Revenue
$1.11M
▼ 53.6% YoY
Diluted EPS
$-0.09
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-06-26
Taysha Gene Therapies, Inc. Q1 FY2024 Earnings Call
Confident tone TSHA-102 clinical progress and REVEAL trial updates Rett syndrome unmet need and market opportunity RMAT designation from FDA
Revenue
$3.41M
▼ 27.5% YoY
Diluted EPS
$-0.10
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-19
Taysha Gene Therapies, Inc. Q4 FY2023 Earnings Call
Confident tone TSHA-102 clinical efficacy and durability REVEAL trial design and enrollment progress Dose escalation strategy and safety monitoring
Revenue
$3.60M*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Taysha Gene Therapies, Inc. Q3 FY2023 Earnings Call
Revenue
$4.75M
Diluted EPS
$-0.93
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Taysha Gene Therapies, Inc. Q2 FY2023 Earnings Call
Revenue
$2.40M
Diluted EPS
$-0.38
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Taysha Gene Therapies, Inc. Q1 FY2023 Earnings Call
Revenue
$4.71M
Diluted EPS
$-0.28
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-28
Taysha Gene Therapies, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Taysha Gene Therapies, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-0.65
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Taysha Gene Therapies, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-0.85
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Taysha Gene Therapies, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-1.32
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
Taysha Gene Therapies, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Taysha Gene Therapies, Inc. Q3 FY2021 Earnings Call
Diluted EPS
$-1.35
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
Taysha Gene Therapies, Inc. Q2 FY2021 Earnings Call
Diluted EPS
$-1.09
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Taysha Gene Therapies, Inc. Q1 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-03
Taysha Gene Therapies, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–24 of 24 earnings calls
Key facts CIK 1806310 CUSIP 877619106 13F (30d) 210 filings 204 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)